Vetoquinol (VETO) EUR2.5

Vetoquinol SA is a France-based company that specializes in the research, development, manufacture, marketing and sale of veterinary drugs and products. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The Company markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. It trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.